Daiwa Securities Group Inc. grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 42.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,137 shares of the medical instruments supplier’s stock after purchasing an additional 2,727 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Becton, Dickinson and were worth $1,790,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Becton, Dickinson and by 8.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after acquiring an additional 1,353,780 shares in the last quarter. BlackRock Inc. raised its stake in shares of Becton, Dickinson and by 2,427.8% during the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after acquiring an additional 15,887,611 shares in the last quarter. State Street Corp raised its stake in shares of Becton, Dickinson and by 3.5% during the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after acquiring an additional 342,873 shares in the last quarter. Northern Trust Corp raised its stake in shares of Becton, Dickinson and by 4.0% during the 2nd quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock worth $549,028,000 after acquiring an additional 106,966 shares in the last quarter. Finally, Fiera Capital Corp raised its stake in shares of Becton, Dickinson and by 7.1% during the 2nd quarter. Fiera Capital Corp now owns 2,782,146 shares of the medical instruments supplier’s stock worth $542,825,000 after acquiring an additional 183,372 shares in the last quarter. Institutional investors and hedge funds own 86.71% of the company’s stock.

Becton, Dickinson and Company (NYSE BDX) opened at $219.23 on Friday. The company has a debt-to-equity ratio of 1.48, a quick ratio of 5.01 and a current ratio of 5.56. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $225.23. The stock has a market cap of $49,889.07, a P/E ratio of 23.10, a price-to-earnings-growth ratio of 1.72 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating the consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The business’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.12 EPS. equities research analysts expect that Becton, Dickinson and Company will post 10.63 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/11/12/daiwa-securities-group-inc-acquires-2727-shares-of-becton-dickinson-and-company-bdx.html.

In other news, insider Gary M. Cohen sold 15,512 shares of the company’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Ribo Alberto Mas sold 7,463 shares of the company’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $201.41, for a total transaction of $1,503,122.83. Following the completion of the sale, the executive vice president now directly owns 29,323 shares in the company, valued at $5,905,945.43. The disclosure for this sale can be found here. Insiders sold a total of 60,650 shares of company stock worth $12,223,970 over the last ninety days. Insiders own 1.40% of the company’s stock.

BDX has been the subject of several recent analyst reports. Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Zacks Investment Research lowered shares of Becton, Dickinson and from a “hold” rating to a “sell” rating in a research note on Monday, October 9th. Royal Bank Of Canada reiterated a “hold” rating and set a $210.00 price objective on shares of Becton, Dickinson and in a research note on Wednesday, October 25th. Bank of America Corporation reiterated a “buy” rating and set a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Finally, Wells Fargo & Company initiated coverage on shares of Becton, Dickinson and in a research note on Friday, September 22nd. They set an “outperform” rating and a $225.00 price objective for the company. Five analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $213.47.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.